Cellebrite DI Ltd. Class A Ordinary Shares (CLBT) is a publicly traded Technology sector company. As of May 21, 2026, CLBT trades at $13.35 with a market cap of $3.40B and a P/E ratio of 0.00. CLBT moved -0.45% today. Year to date, CLBT is -25.80%; over the trailing twelve months it is -21.41%. Its 52-week range spans $11.02 to $26.30. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces CLBT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cellebrite Reports 19% Revenue Growth and 21% ARR Rise While Price Target Hits $15: Cellebrite DI Ltd. reported Q1 2026 revenue of $128.3 million, up 19% year-over-year, and earned $0.12 per share, surpassing estimates. Annual recurring revenue rose 21% to $493 million and adjusted EBITDA increased 29% to $30.6 million while Needham set a $15.00 price target implying a 15.12% upside.
| Metric | Value |
|---|---|
| Price | $13.35 |
| Market Cap | $3.40B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.30 |
| 52-Week Low | $11.02 |
| Volume | 300 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover CLBT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.